COMMUNIQUÉS West-GlobeNewswire

Sangamo Therapeutics Launches Auction Process for Clinical-Stage Chronic Neuropathic Pain Program
13/10/2026
Auction process initiated for ST-503 program for chronic neuropathic pain, expected to be completed in fourth quarter of 2026 Previously announced asset sale transactions with PTC and Lilly have closed, generating $163. [...]
Acquisition of Own Shares
13/10/2026
Mechelen, Belgium; October 13, 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") [...]
Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease
13/10/2026
-- NOV-ERA is designed to assess the efficacy and safety of ontunisertib in approximately 320 patients with symptomatic Fibrostenosing Crohn's disease (FSCD) -- -- Global, randomized, placebo-controlled, dose-ranging [...]
OrthoPediatrics Corp. to Report Third Quarter Financial Results on October 27, 2026
13/10/2026
WARSAW, Ind., Oct. 13, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced [...]
Rani Therapeutics to Participate in the Chardan Healthcare Conference
13/10/2026
SAN JOSE, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the company’s [...]
CapsoVision to Present at the 20th Annual LD Micro Main Event
13/10/2026
SARATOGA, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced [...]
Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist
13/10/2026
Mean weight reduction ranged from 1.5% to 3.2% at Day 29 across Cohorts 1-4, compared with 0.1% for pooled placebo. No severe or serious TEAEs, no TEAE-related dose modifications, and no TEAE-related discontinuations [...]
Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
13/10/2026
Collaboration will combine Zealand Pharma’s expertise in metabolic health with Generate’s proprietary generative AI platform to create multispecific drug candidates with tailored biological functions Generate will [...]
Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases
13/10/2026
Press release – No. 20 / 2026 Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases Collaboration will combine [...]
TRexBio Announces Closing of Initial Public Offering
13/10/2026
SOUTH SAN FRANCISCO, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- TRex Bio, Inc. (“TRexBio”) (Nasdaq: TRXB), a clinical-stage biotechnology company focused on tissue Treg biology for the discovery and development of [...]
Orum Therapeutics Doses First Patient in Phase 1 Trial of ORM-1153, a CD123-GSPT1 Degrader-Antibody Conjugate
14/10/2026
BOSTON and DAEJEON, South Korea, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Orum Therapeutics (“Orum” or the “Company”) (KRX: 475830), a biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today [...]
Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity
14/10/2026
-- Launch follows MHLW approval of IMCIVREE for acquired hypothalamic obesity and inclusion on Japan's National Health Insurance drug price list -- -- IMCIVREE is the first approved therapy in Japan for patients living [...]
Assisting Hands Home Care - The Villages Doubles in Size in 2026 as Demand for In-Home Care Grows
13/10/2026
Following its 2025 Top Producer Award, the local agency has doubled its clients served, caregiving team, and service capacity while expanding care for elderly, veterans and individuals with special needs. The Villages, [...]
Lite Strategy Marks 15 Years of Litecoin with Launch of "Proof of Time" Public Industry Archive
13/10/2026
First Nasdaq-Listed Company with Litecoin Reserve Treasury Celebrates 15 Years of Uptime and Real-World Payments with an Industry-Wide Storytelling Campaign SAN DIEGO, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Lite Strategy, [...]
Shoreline Medical Administration, CHUM Health and Cellution Biologics Launch Elite Graft Program for Advanced Wound Care
13/10/2026
New collaborative program brings together an industry leading biologic graft, wound care specific revenue cycle management and the only clawback protection program in one coordinated solution ROSWELL, Ga., Oct. 13, 2026 [...]
Eye2Eye Foundation Announces Free Thyroid Eye Disease Patient Seminars in Houston and Woodland Hills Featuring Dr. Raymond Douglas
13/10/2026
Complimentary gatherings in Houston and Woodland Hills will connect people affected by thyroid eye disease with clinical experts, patient-focused education and practical financial-navigation guidance. Beverly Hills, CA [...]
Giraffe Bio raises $6.4M Seed to scale next-generation reagents for copper mining
13/10/2026
Funding will accelerate manufacturing scale-up and industrial validation of drop-in biochemical flotation reagents designed to help miners recover more copper from increasingly complex ores BUENOS AIRES, Argentina and [...]
Stride Autism Centers Expands Early Intervention ABA Access with New Chicago Location
13/10/2026
Avondale–Logan Square center now accepting children ages 2–6 for individualized, center-based ABA therapy CHICAGO, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Stride Autism Centers, a leading provider of Applied Behavior Analysis [...]
Alaunos Therapeutics Announces Acquisition of Velaris Therapeutics
13/10/2026
Acquisition of Velaris and concurrent oversubscribed $350 million private placement positions the Company to deliver multiple proof-of-concept datasets in pulmonary arterial hypertension Velaris Therapeutics, the ninth [...]

Pages